TRENDSPOTTER: The Slippery Slope from Tool Maker to Drug Developer | GenomeWeb

SO YOUR company’s stock is down – way down from where you think it ought to be and way below its 52-week high. You find yourself fielding calls from any one of the following: irate, disgruntled, or disappointed shareholders. What a distraction! What should you do?

Well for one, be patient, be polite and keep your cool. Remember, many of your shareholders have no experience in a down market and they are hurting.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.